Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study.

McDonald JU, Rigsby P, Dougall T, Engelhardt OG; Study Participants.

Vaccine. 2018 Nov 29;36(50):7641-7649. doi: 10.1016/j.vaccine.2018.10.087. Epub 2018 Oct 30.

2.

Mutation of Influenza A Virus PA-X Decreases Pathogenicity in Chicken Embryos and Can Increase the Yield of Reassortant Candidate Vaccine Viruses.

Hussain S, Turnbull ML, Wise HM, Jagger BW, Beard PM, Kovacikova K, Taubenberger JK, Vervelde L, Engelhardt OG, Digard P.

J Virol. 2019 Jan 4;93(2). pii: e01551-18. doi: 10.1128/JVI.01551-18. Print 2019 Jan 15.

3.

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Dong W, Bhide Y, Sicca F, Meijerhof T, Guilfoyle K, Engelhardt OG, Boon L, de Haan CAM, Carnell G, Temperton N, de Vries-Idema J, Kelvin D, Huckriede A.

Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018.

4.

Workshop report: Experimental animal models for universal influenza vaccines.

D'Alessio F, Koopman G, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG.

Vaccine. 2018 Nov 12;36(46):6895-6901. doi: 10.1016/j.vaccine.2018.10.024. Epub 2018 Oct 16.

PMID:
30340885
5.

Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.

Engelhardt OG, Edge C, Dunleavy U, Guilfoyle K, Harvey R, Major D, Newman R, Penn R, Skeldon S, Storey C, Wheeler J, Wood J, Minor P.

Vaccine. 2018 Jul 5;36(29):4339-4345. doi: 10.1016/j.vaccine.2018.05.076. Epub 2018 Jun 9.

6.

Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.

Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, Neuzil KM, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J.

Vaccine. 2018 Feb 8;36(7):932-938. doi: 10.1016/j.vaccine.2017.11.061. Epub 2017 Dec 6.

7.

Workshop report: Immunoassay standardisation for "universal" influenza vaccines.

Pavlova S, D'Alessio F, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG.

Influenza Other Respir Viruses. 2017 May;11(3):194-201. doi: 10.1111/irv.12445. Epub 2017 Apr 8. Review.

8.

The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein.

Nicolson C, Harvey R, Engelhardt OG, Robertson JS.

PLoS One. 2016 Nov 18;11(11):e0166761. doi: 10.1371/journal.pone.0166761. eCollection 2016.

9.

CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.

Horby PW, Laurie KL, Cowling BJ, Engelhardt OG, Sturm-Ramirez K, Sanchez JL, Katz JM, Uyeki TM, Wood J, Van Kerkhove MD; CONSISE Steering Committee.

Influenza Other Respir Viruses. 2017 Jan;11(1):2-14. doi: 10.1111/irv.12411. Epub 2016 Aug 9.

10.

Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.

Eichelberger MC, Couzens L, Gao Y, Levine M, Katz J, Wagner R, Thompson CI, Höschler K, Laurie K, Bai T, Engelhardt OG; ELLA study participants, Wood J.

Vaccine. 2016 Jan 20;34(4):458-465. doi: 10.1016/j.vaccine.2015.12.022. Epub 2015 Dec 18.

11.

International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE.

Laurie KL, Engelhardt OG, Wood J, Heath A, Katz JM, Peiris M, Hoschler K, Hungnes O, Zhang W, Van Kerkhove MD; CONSISE Laboratory Working Group participants.

Clin Vaccine Immunol. 2015 Aug;22(8):957-64. doi: 10.1128/CVI.00278-15. Epub 2015 Jun 24.

12.

A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccine.

Harvey R, Johnson RE, MacLellan-Gibson K, Robertson JS, Engelhardt OG.

Influenza Other Respir Viruses. 2014 Nov;8(6):605-12. doi: 10.1111/irv.12274. Epub 2014 Aug 2.

13.

The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.

Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S.

PLoS One. 2014 Aug 1;9(8):e103294. doi: 10.1371/journal.pone.0103294. eCollection 2014.

14.

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013.

Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Schultz-Cherry S, Shu Y, Smith D, Tashiro M, Wang D, Webby R, Xu X, Ye Z, Zhang W; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014.

Vaccine. 2014 Aug 20;32(37):4713-25. doi: 10.1016/j.vaccine.2014.02.014. Epub 2014 Feb 28.

15.

The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy.

Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A; CONSISE steering committee.

Influenza Other Respir Viruses. 2013 May;7(3):231-4. doi: 10.1111/irv.12068. Epub 2012 Dec 26.

16.

WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011.

Klimov AI, Garten R, Russell C, Barr IG, Besselaar TG, Daniels R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Smith D, Tashiro M, Xu X, Webby R, Wang D, Ye Z, Yuelong S, Zhang W, Cox N; Writing Committee of the World Health Organization Consultation on Southern Hemisphere Influenza Vaccine Composition for 2012.

Vaccine. 2012 Oct 5;30(45):6461-71. doi: 10.1016/j.vaccine.2012.07.089. Epub 2012 Aug 20.

17.

Many ways to make an influenza virus--review of influenza virus reverse genetics methods.

Engelhardt OG.

Influenza Other Respir Viruses. 2013 May;7(3):249-56. doi: 10.1111/j.1750-2659.2012.00392.x. Epub 2012 Jun 19. Review.

18.

Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].

Johnson RE, Hamill M, Harvey R, Nicolson C, Robertson JS, Engelhardt OG.

PLoS One. 2012;7(5):e36241. doi: 10.1371/journal.pone.0036241. Epub 2012 May 11. Erratum in: PLoS One. 2012;7(6): doi/10.1371/annotation/1fcf03a1-a452-414f-bf45-919a059a7ba7.

19.

Application of deglycosylation to SDS PAGE analysis improves calibration of influenza antigen standards.

Harvey R, Hamill M, Robertson JS, Minor PD, Vodeiko GM, Weir JP, Takahashi H, Harada Y, Itamura S, Bamford P, Dalla Pozza T, Engelhardt OG.

Biologicals. 2012 Jan;40(1):96-9. doi: 10.1016/j.biologicals.2011.12.009. Epub 2012 Jan 12.

PMID:
22244521
20.

An additional oligosaccharide moiety in the HA of a pandemic influenza H1N1 candidate vaccine virus confers increased antigen yield in eggs.

Nicolson C, Harvey R, Johnson R, Guilfoyle K, Engelhardt OG, Robertson JS.

Vaccine. 2012 Jan 17;30(4):745-51. doi: 10.1016/j.vaccine.2011.11.081. Epub 2011 Nov 30.

PMID:
22138177
21.

Characterization of the interaction between the influenza A virus polymerase subunit PB1 and the host nuclear import factor Ran-binding protein 5.

Hutchinson EC, Orr OE, Man Liu S, Engelhardt OG, Fodor E.

J Gen Virol. 2011 Aug;92(Pt 8):1859-69. doi: 10.1099/vir.0.032813-0. Epub 2011 May 11.

PMID:
21562121
22.

Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules.

Harvey R, Guilfoyle KA, Roseby S, Robertson JS, Engelhardt OG.

J Virol. 2011 Jun;85(12):6086-90. doi: 10.1128/JVI.00096-11. Epub 2011 Apr 13.

23.

The development of vaccine viruses against pandemic A(H1N1) influenza.

Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S, Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z, Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A, Cox NJ, Donis RO.

Vaccine. 2011 Feb 17;29(9):1836-43. doi: 10.1016/j.vaccine.2010.12.044. Epub 2011 Jan 1.

PMID:
21199698
24.

Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules.

Harvey R, Nicolson C, Johnson RE, Guilfoyle KA, Major DL, Robertson JS, Engelhardt OG.

Vaccine. 2010 Nov 23;28(50):8008-14. doi: 10.1016/j.vaccine.2010.09.006. Epub 2010 Oct 8.

PMID:
20934460
25.

Developing vaccines to combat pandemic influenza.

Robertson JS, Engelhardt OG.

Viruses. 2010 Feb;2(2):532-46. doi: 10.3390/v2020532. Epub 2010 Feb 2.

26.

Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season.

Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A, Odagiri T, Smith D, Russell C, Tashiro M, Webby R, Wood J, Ye Z, Zhang W; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2009-2010.

Vaccine. 2010 Feb 3;28(5):1156-67. doi: 10.1016/j.vaccine.2009.11.043. Epub 2009 Dec 9.

PMID:
20004635
27.

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JG, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwartz R, Smith JS, Sugawara K, Trusheim H, Tsai TF, Krause R.

Vaccine. 2009 May 14;27(22):2907-13. doi: 10.1016/j.vaccine.2009.02.064. Epub 2009 Feb 27. Review.

PMID:
19366582
28.

Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1).

Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG.

Vaccine. 2008 Dec 2;26(51):6550-4. doi: 10.1016/j.vaccine.2008.09.050.

PMID:
18840494
29.

Role of ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase complex.

Deng T, Engelhardt OG, Thomas B, Akoulitchev AV, Brownlee GG, Fodor E.

J Virol. 2006 Dec;80(24):11911-9. Epub 2006 Sep 27.

30.

Functional association between viral and cellular transcription during influenza virus infection.

Engelhardt OG, Fodor E.

Rev Med Virol. 2006 Sep-Oct;16(5):329-45. Review.

PMID:
16933365
31.

Influenza virus inhibits RNA polymerase II elongation.

Chan AY, Vreede FT, Smith M, Engelhardt OG, Fodor E.

Virology. 2006 Jul 20;351(1):210-7. Epub 2006 Apr 19.

32.
33.
34.
35.
36.

Rescue of recombinant Thogoto virus from cloned cDNA.

Wagner E, Engelhardt OG, Gruber S, Haller O, Kochs G.

J Virol. 2001 Oct;75(19):9282-6.

37.

Formation of virus-like particles from cloned cDNAs of Thogoto virus.

Wagner E, Engelhardt OG, Weber F, Haller O, Kochs G.

J Gen Virol. 2000 Dec;81(Pt 12):2849-53.

PMID:
11086115
38.

Rescue of influenza A virus from recombinant DNA.

Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A.

J Virol. 1999 Nov;73(11):9679-82.

39.
40.

Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa.

Gilleland HE Jr, Gilleland LB, Staczek J, Harty RN, Garcia-Sastre A, Engelhardt OG, Palese P.

Behring Inst Mitt. 1997 Feb;(98):291-301.

PMID:
9382753
41.

Negative-strand RNA viruses: genetic engineering and applications.

Palese P, Zheng H, Engelhardt OG, Pleschka S, García-Sastre A.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11354-8. Review.

42.

A plasmid-based reverse genetics system for influenza A virus.

Pleschka S, Jaskunas R, Engelhardt OG, Zürcher T, Palese P, García-Sastre A.

J Virol. 1996 Jun;70(6):4188-92.

43.

Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Muster T, Ferko B, Klima A, Purtscher M, Trkola A, Schulz P, Grassauer A, Engelhardt OG, García-Sástre A, Palese P, et al.

J Virol. 1995 Nov;69(11):6678-86.

Supplemental Content

Loading ...
Support Center